Company profile
PROQR THERAPEUTICS N.V.
NASDAQ:PRQRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELUFORSEN | phase1_2 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03913143 | phase2_3 | active_not_recruiting | 2019-04-04 | 2022-01-31 | ProQR Therapeutics | A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) |
| NCT04123626 | phase1_2 | active_not_recruiting | 2019-10-07 | 2022-06-07 | ProQR Therapeutics | A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene |
| NCT04855045 | phase2_3 | unknown | 2021-03-23 | 2023-12-01 | ProQR Therapeutics | An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. |
| NCT02532764 | phase1_2 | completed | 2015-06-01 | 2017-09-14 | ProQR Therapeutics | Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients |
| NCT02564354 | phase1 | completed | 2015-09-01 | 2016-09-01 | ProQR Therapeutics | Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation |
FDA applications (0)
No records yet.